Treatment
Semaglutide clinical trials
We’re tracking 138 recruiting studies that include Semaglutide, each written for real people, not researchers, below.
Recruiting studies
- NCT06717698RecruitingPhase 2
Testing a new medicine for kidney damage in chronic kidney disease
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
San Dimas, CaliforniaAges 18 years+ - NCT06706284RecruitingPhase 4
GLP-1 agonist for diabetes after spinal cord injury
This trial tests whether a GLP-1 agonist (a type of diabetes medicine that also helps with weight loss) is safe and effective for people with spinal cord injury and type 2 diabetes who are not on other glucose-lowering drugs.
San Antonio, TexasAges 18–70 - NCT06613854RecruitingPhase 4
Early combination therapy for type 2 diabetes
This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.
LjubljanaAges 18–70 - NCT06548490RecruitingPhase 2
Semaglutide for Opioid Use Disorder
This study tests whether a once-weekly injection of semaglutide (a GLP-1 receptor agonist) can reduce opioid use in people who are already on buprenorphine or methadone but still using opioids. It lasts about 19 weeks.
Baltimore, MarylandAges 18–75 - NCT06497595Recruiting
Lifestyle program to prevent muscle loss in older adults with diabetes on semaglutide
This trial tests whether a lifestyle program (diet and exercise) can help prevent muscle loss in people 65 and older with type 2 diabetes and obesity who are taking semaglutide. It may help you keep your strength and independence while losing weight.
Jerusalem, IsraelAges 65 years+ - NCT06423599RecruitingPhase 2/Phase 3
Weight Loss for Obesity and Heart Failure
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
CopenhagenAges 18 years+ - NCT06411210RecruitingPhase 2
Weight loss medication for young adults with type 1 diabetes
This study tests whether a GLP-1 medication (a type of drug that helps with weight loss) can safely and effectively help young adults with type 1 diabetes who also have obesity. It aims to see if adding this treatment to insulin can improve weight and blood sugar control.
New Haven, ConnecticutAges 18–30 - NCT06410352RecruitingPhase 4
Weight loss methods for longer life with metabolic syndrome
This trial tests weight loss methods in people with type 2 diabetes, high blood pressure, and excess weight. It aims to see if losing 15-20% of body weight can help people live longer and healthier.
Astana, AstanaAges 35–65 - NCT06380426Recruiting
Semaglutide for teens and adults with genetic obesity
This study looks at how semaglutide works in real life for people with obesity caused by a single gene change. If you or your teenager have this type of obesity and are taking or about to start semaglutide, you may be able to join.
ParisAges 12 years+ - NCT06396416RecruitingPhase 4
Obesity management after kidney transplant
This study tests whether a weight loss medication (semaglutide) can help manage obesity in people who have had a kidney transplant or are at high risk. It aims to improve health outcomes and prevent further kidney decline.
London, OntarioAges 18 years+ - NCT06338553RecruitingEarly Phase 1
GLP-1 drug for early type 1 diabetes
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
Nashville, TennesseeAges 12–50 - NCT05938712RecruitingPhase 2
Kidney transplant trial using two diabetes medicines safely
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Toronto, OntarioAges 18 years+ - NCT05586802RecruitingPhase 3
Balancing sex hormones to improve metabolism and fertility in Klinefelter
This study tests whether adjusting sex-hormone levels can improve body metabolism and reproductive hormone balance in people with Klinefelter syndrome. Depending on the design, you may be looking at fertility preservation and/or metabolic health.
LausanneAges 16–65 - NCT05424003RecruitingPhase 2
Semaglutide to prevent weight gain after liver transplant
This trial tests semaglutide (a diabetes/weight-loss medicine) to help prevent weight gain after liver transplant. It is also looking at blood sugar and safety while you continue your transplant medicines.
Richmond, VirginiaAges 18–75 - NCT05305794RecruitingPhase 3
Weekly shot to improve blood sugar control in double diabetes
This trial tests a weekly injection (similar to Ozempic) for people with type 1 diabetes who also have features of type 2 diabetes (often called 'double diabetes'). The goal is to see if this extra treatment can help lower blood sugar and improve overall diabetes management.
DijonAges 18 years+ - NCT05173714RecruitingPhase 2
Sit Less and Move More program for people with CKD
This Phase 2 study tests a program to help people with chronic kidney disease (CKD) sit less and move more, plus a medication (semaglutide) for those who qualify. It may help improve health and day-to-day activity while monitoring safety closely.
Stanford, CaliforniaAges 20 years+ - NCT05119179RecruitingPhase 4
Testing how genetics affect GLP-1 response in prediabetes
This study looks at how your genes may change how well a GLP-1–type medicine works to improve prediabetes. It focuses on adults at higher risk of developing diabetes, especially people of Mexican-American background.
Brownsville, TexasAges 18 years+ - NCT05071898RecruitingPhase 1
Studying how genetics affect response to GLP-1 weight-loss drugs
This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.
Lancaster, PennsylvaniaAges 18–89
Common questions
- Are there clinical trials studying Semaglutide?
- Yes. Clin2 currently lists 138 recruiting studies that include Semaglutide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Semaglutide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Semaglutide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Semaglutide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.